How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic review

Published:April 23, 2020DOI:



      SARS-CoV-2 infection has now a global resonance. Data on how COVID-19 is affecting immunocompromised patients are however few. With our study we aimed to systematically review the current knowledge on SARS-CoV-2 cases in children and adults with immunosuppression, to evaluate outcomes in this special population.


      A systematic review of literature was carried out to identify relevant articles, searching the EMBASE, Medline, and Google Scholar databases. Studies reporting data on pre-defined outcomes and related to immunosuppressed adults and children with SARS-CoV-2 were included.


      Sixteen relevant articles were identified with 110 immunosuppressed patients, mostly presenting cancer, along with transplantation and immunodeficiency. Cancer was more often associated with a more severe course, but not necessarily with a bad prognosis. Our data show that both children and adults with immunosuppression seem to have a favorable disease course, as compared to the general population.


      Immunosuppressed patients with COVID-19 seem to be few in relation to the overall figures, and to present a favorable outcome as compared to other comorbidities. This might be explained by a hypothetical protective role of a weaker immune response, determining a milder disease presentation and thus underdiagnosis. Nevertheless, surveillance on this special population should be encouraged.


      To read this article in full you will need to make a payment


      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • D'Antiga L.
        Coronaviruses and immunosuppressed patients. The facts during the third epidemic.
        Liver Transpl [Internet]. 2020; (Available from): 0-1
        • Abdulamir A.S.
        • Hafidh R.R.
        The Possible Immunological Pathways for the Variable Immunopathogenesis of COVID—19 Infections among Healthy Adults, Elderly and Children.
        Electron J Gen Med. 2020; 17
        • Liberati A.
        • Altman D.G.
        • Tetzlaff J.
        • Mulrow C.
        • Gotzsche P.C.
        • Ioannidis J.P.A.
        • et al.
        The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
        BMJ. Jul 2009; 339 (b2700)
        • Aslam S.
        • Mehra M.R.
        COVID-19: Yet Another Coronavirus Challenge in Transplantation.
        J Hear Lung Transplant [Internet]. 2020; (Available from
        • Guan W.-J.
        • Ni Z.-Y.
        • Hu Y.
        • Liang W.-H.
        • Ou C.-Q.
        • He J.-X.
        • et al.
        Clinical Characteristics of Coronavirus Disease 2019 in China.
        N Engl J Med [Internet]. 2020; (Available from): 1-13
        • Huang C.
        • Wang Y.
        • Li X.
        • Ren L.
        • Zhao J.
        • Hu Y.
        • et al.
        Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.
        Lancet. 2020; 395: 497-506
        • Analysis on 54 Mortality Cases of Coronavirus Disease 2019 in the Republic of Korea from January 19 to March 10, 2020
        J Korean Med Sci.
        . 2020; 35: 1-9
        • Lescure F.-X.
        • Bouadma L.
        • Nguyen D.
        • Parisey M.
        • Wicky P.-H.
        • Behillil S.
        • et al.
        Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
        Lancet Infect Dis. 2020; 2: 1-10
        • Ludvigsson J.F.
        Systematic review of COVID-19 in children show milder cases and a better prognosis than adults.
        Acta Paediatr [Internet]. 2020; (Available from): 0-3
        • Tian S.
        • Hu W.
        • Niu L.
        • Liu H.
        • Xu H.
        • Xiao S.-Y.
        Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.
        J Thorac Oncol [Internet]. 2020; (Available from)
        • Yang X.
        • Yu Y.
        • Xu J.
        • Shu H.
        • Xia J.
        • Liu H.
        • et al.
        Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.
        Lancet Respir Med. 2020; 2600: 1-7
        • Yu J.
        • Ouyang W.
        • Chua M.L.K.
        • Xie C.
        SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.
        JAMA Oncol. 2020; : 25-27
        • Zhou F.
        • Yu T.
        • Du R.
        • Fan G.
        • Liu Y.
        • Liu Z.
        • et al.
        Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
        Lancet [Internet]. 2020; 395: 1054-1062
        • Guillen E.
        • Pineiro G.J.
        • Revuelta I.
        • Rodriguez D.
        • Bodro M.
        • Moreno A.
        • et al.
        Case report of COVID-19 in a kidney transplant recipient: Does immunosuppression alter the clinical presentation?.
        Am J Transplant [Internet]. 2020; : 0-3
        • Wang Z.
        • Yang B.
        • Li Q.
        • Wen L.
        • Zhang R.
        Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China.
        Clin Infect Dis. 2020;
        • Guan W.
        • Ph D.
        • Liang W.
        • Zhao Y.
        • Med M.
        • Liang H.
        • et al.
        Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis.
        European Respiratory Journal. 2020; (Preprint)
        • Liang W.
        • Guan W.
        • Chen R.
        • Wang W.
        • Li J.
        • Xu K.
        • et al.
        Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
        Lancet Oncol. 2020; 21: 335-337
        • Zhang L.
        • Zhu F.
        • Xie L.
        • Wang C.
        • Wang J.
        • Chen R.
        • et al.
        Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China.
        Ann Oncol Off J Eur Soc Med Oncol. Mar 2020;
        • Li Q.
        • Guan X.
        • Wu P.
        • Wang X.
        • Zhou L.
        • Tong Y.
        • et al.
        Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia.
        N Engl J Med. 2020; : 1-9
        • Molloy E.J.
        • Bearer C.F.
        COVID-19 in children and altered inflammatory responses.
        Pediatric research, United States2020
        • Brodin P.
        Why is COVID-19 so mild in children?.
        Acta Paediatr. 2020; : 0-2
        • Xia Y.
        • Jin R.
        • Zhao J.
        • Li W.
        • Shen H.
        Risk of COVID-19 for patients with cancer.
        Lancet Oncol [Internet]. 2020; 21: e180
        • Shrestha S.S.
        • Swerdlow D.L.
        • Borse R.H.
        • Prabhu V.S.
        • Finelli L.
        • Atkins C.Y.
        • et al.
        Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010).
        Clin Infect Dis. Jan 2011; 52 (S75–S82)
        • Memoli M.J.
        • Athota R.
        • Reed S.
        • Czajkowski L.
        • Bristol T.
        • Proudfoot K.
        • et al.
        The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts.
        Clin Infect Dis. Jan 2014; 58: 214-224
        • Hui D.S.
        • Azhar E.I.
        • Kim Y.-J.
        • Memish Z.A.
        • Oh M.-D.
        • Zumla A.
        Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission.
        Lancet Infect Dis. Aug 2018; 18 (e217–e227)
        • Mandl J.N.
        • Ahmed R.
        • Barreiro L.B.
        • Daszak P.
        • Epstein J.H.
        • Virgin H.W.
        • et al.
        Reservoir host immune responses to emerging zoonotic viruses.
        Cell. Jan 2015; 160: 20-35
        • Mandl J.N.
        • Schneider C.
        • Schneider D.S.
        • Baker M.L.
        Going to Bat(s) for Studies of Disease Tolerance.
        Front Immunol. 2018; 9: 2112
      1. King F.Interim Recommendations for the use of Tocilizumab in the Management of Patients who have Severe COVID-19 with Suspected Hyperinflammation Protocol: Interim Recommendations for the use of Tocilizumab in the Management of Patients who have Severe COVID-19. 2020;1–5. Available from:

        • Hanna T.P.
        • Evans G.A.
        • Booth C.M.
        Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic.
        Nat Rev Clin Oncol. Apr 2020;
        • Wang Z.
        • Wang J.
        • He J.
        Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China.
        JAMA Oncol [Internet]. 2020 Apr 1;
        • Al-Shamsi H.O.
        • Alhazzani W.
        • Alhuraiji A.
        • Coomes E.A.
        • Chemaly R.F.
        • Almuhanna M.
        • et al.
        A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.
        Oncologist. Apr 2020;
        • Sinha I.P.
        • Harwood R.
        • Semple M.G.
        • Hawcutt D.B.
        • Thursfield R.
        • Narayan O.
        • et al.
        COVID-19 infection in children.
        Lancet Respir Med [Internet]. 2020; 2019: 2019-2020